Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Proteostasis Therapeutics Announces Expansion of Collaboration with The Scripps Research Institute

Published: Wednesday, August 01, 2012
Last Updated: Friday, August 03, 2012
Bookmark and Share
The expansion encompasses an additional funded research project focused on biology and the testing of small molecule modulators of protein folding and trafficking for the treatment of cystic fibrosis.

This expansion follows the Company’s recently announced collaboration with the Cystic Fibrosis Foundation to research, develop, and commercialize therapies to treat patients with the most common mutation of the cystic fibrosis transmembrane conductance regulator (CFTR), Delta F508.

“This expanded collaboration will allow us to accelerate our CF program as we work to advance our most promising series to lead optimization this year,” said Mark Enyedy, Chief Executive Officer of Proteostasis Therapeutics.

Working with the laboratory of William Balch, Ph.D., Professor of Cell Biology at TSRI, scientists at Proteostasis Therapeutics have used an integrated platform comprised of genomics, proteomics, functional assays, and medicinal chemistry to identify compounds that regulate key folding and trafficking pathways in the cell. To date, these compounds have demonstrated significant efficacy in CF-specific cellular models. Under the expanded collaboration, Proteostasis Therapeutics will provide funding for this research and will have exclusive rights to license any technology originating from the research.

“We are excited to deepen our relationship with Proteostasis Therapeutics to develop novel approaches that manage the root cause of the problem of this devastating disease,” added Dr. Balch.

This newly expanded collaboration will enhance the ability of Proteostasis Therapeutics to perform chaperone-based high throughput screening in multiple disease relevant cellular models to identify Proteostasis Regulators that will correct the folding, trafficking and function of Delta F508 CFTR, both alone and in combination with agents currently in development or on the market.

“Dr. Balch’s expertise in CF biology and protein homeostasis complements our proprietary technology for characterizing proteostasis network pathways in normal and disease states. The expansion of this collaboration further underscores our commitment to working with leading academic scientists and institutions in our focus areas in neurodegenerative and orphan diseases,” stated Peter Reinhart, Chief Scientific Officer of Proteostasis Therapeutics.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Designing Drugs with a Whole New Toolbox
Researchers develop methods to design small, targeted proteins with shapes not found in nature.
Small Molecules Lead to a Big Change in Reaction Outcomes
Scientists have changed the behaviour of a group of molecules involved in carbon-oxygen bond synthesis.
Targeting Fat to Treat Cancer
Researchers develop novel cancer treatment that halts fat synthesis in cells, stunting tumors.
Hyperstable Peptides for 'On-Demand' Drugs
These small molecules can fold into different conformations that could allow for greater flexibility in precision drug design
Drug Leads Identified to Combat Heart Disease
Using three supercomputers, researchers surveyed protein structures through accelerated molecular dynamics.
Accelerating the Path to Molecules for Medicine
Researchers convert carbon-hydrogen bonds into nitriles - converting organic molecules into components of medicines.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
Game Changing Antibacterial Drug Research
Researchers publish report on the synthesis of a newly discovered “game-changing” antibiotic, Teixobactin.
New Way of Displaying 3D Molecular Structures
Metal-organic frameworks provide a new platform for solving the structure of hard-to-study samples.
Agent Blocks Pain Without Morphine's Side Effects
Scientists have synthesised a molecule with specific pain-relief properties and has shown its efficacy in mice.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!